A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: William D. Tap, Brian Andrew Van Tine, Anthony D. Elias, Michael B. Livingston, Mark Agulnik, Matthew M. Cooney, Bartosz Chmielowski, Andrew Jacob Brenner, Gregory K. Pennock, Neeta Somaiah, Long H. Dang, Gary G. Tian, Robin Lewis Jones, Scott H. Okuno, Nick Loizos, Johannes Nippgen, Gary K. Schwartz
Institutions: Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, University of Colorado Cancer Center, Carolinas Healthcare System, Northwestern University, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, University of California, Los Angeles, The University of Texas at San Antonio Health Science Center, The University of Texas MD Anderson Cancer Center, Medical University of South Carolina, University of Florida, Seattle Cancer Care Alliance, Mayo Clinic, Eli Lilly (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2600595343